07 June 2020
Visiongain has launched a new pharma report Contrast Media Market Report 2020-2030: Forecasts by Type (Barium-based, Gadolinium-based, Iodinated, Microbubble), Form (Liquid, Paste, Powder, Tablet), Modality (X-Ray/CT, MRI, Ultrasound), Route (Injectable, Oral, Rectal), Application (Cancer, Cardiovascular disorders, Gastrointestinal Disorders, Musculoskeletal Disorders, Nephrological Disorders, Neurological Disorders, Others), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global contrast media market is anticipated to grow at a lucrative CAGR of ~xyz% and anticipated to reach USD xyz billion by 2020 on account of growing CVDs and cancer patient pool coupled with the growing number of approvals of contrast agents.
The increase in the prevalence of long-term diseases and complex comorbidities has led to an increase in the number of diagnostic imaging tests. These include ultrasound, x-ray, and advanced imaging technologies such as magnetic resonance imaging (MRI) and computed tomography (CT) scans. The role of these tests in identifying the need for treatment/surgery in interventional procedures and perioperative scans before surgery is expected to boost the use of contrast media in imaging procedures.
North America holds the majority of market share followed by Europe and will continue to dominate in the future, as a result, well-established healthcare infrastructure coupled with the availability of advanced technologies. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the contrast media market.
For instance, on 4th November 2019; The U.S. Food and Drug Administration (FDA) approved Clariscan, a macrocyclic, ionic, gadolinium-based, magnetic resonance imaging (MRI) contrast agent, expanding the GE Healthcare portfolio for U.S. patients and radiologists. Clariscan is a gadolinium-based contrast agent indicated for intravenous use with MRI in the brain (intracranial), spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity.
Clariscan has been approved in more than 55 countries globally and has had more than four million patient doses shipped in those countries. It is the latest in a growing range of imaging agents available in the U.S. from GE Healthcare. For more than 40 years, GE agents have been routinely used across MRI, X-ray/computed tomography (CT) and ultrasound to enhance the image and support diagnosis.
The introduction of Clariscan is anticipated to strengthen the company’s clinical offerings for radiologists and thus provide better patient care.
The comprehensive market report features companies such as Bayer AG, Bracco Diagnostic, Inc., CMC Contrast AB, DAIICHI, GE Healthcare, General Electric Company, Guerbet, iMAX, Jodas Expoim, Lantheus Medical Imaging Inc., Magnus Health, Nano Therapeutics Pvt. Ltd., NanoPet Pharma Gmbh, NANOSCAN IMAGING, Spago Nanomedical AB, Subhra Pharma Private Ltd, Taejoon Pharm, Trivitron Healthcare among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.
01 April 2021
Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.